{Zolbetuximab-MMAE: A New Novel Emerging ADC for CLDN18.2-Positive Cancers Tumors Malignancies
Zolbetuximab-MMAE represents is offers provides a significant important promising groundbreaking advance in regarding for the treatment therapy management approach of cancers tumors malignancies expressing overexpressing harboring presenting CLDN18.2. This The It This particular antibody-drug con